The future of bacterial manufacturing is now
By Duncan Emerton, PhD; Director, Custom Intelligence, Informa Pharma Intelligence
The level of regulatory requirements biologics are being subjected to is rising and there is an expectation that in a near future there may be “zero tolerance” towards antibiotic-based selection and production systems.
This will create a considerable impact in the field of protein manufacturing using bacterial systems (e.g. Escherichia coli), meaning that pharmaceutical companies need to start making plans for how they expect to tackle this issue within their own organization - and begin now.
Despite significant challenges arising through new regulatory environments, new opportunities to tackle these hurdles will also be created. One such opportunity presents itself in the form of an original genetic selection technology that uses bacteriocins, recently developed by a synthetic biology start-up, which is looking for partners to license its technology to.
Using bacteriocins allows for antibiotic-free selection of expressing clones, which helps to reduce the spread of antibiotic resistant microbes. Bacteriocins have many unique qualities which make them attractive alternatives to antibiotics in production processes. They are ribosomally-synthesized peptides secreted by bacteria and are needed in lesser quantities to kill bacteria than antibiotics, are less likely to cause microbial resistance, while their small size limits the metabolic strain on the host.
From a manufacturing perspective, this novel selection technology has several advantages: it allows for antibiotic-free selection (i.e. avoids using antimicrobial resistance genes), increases the yield and provides better genetic stability. The technology is also easy to use and is 100% plasmid based. It will also be fully compliant with regulatory guidance from governing bodies such as the FDA and EMA where pressure to avoid antibiotic selection is only set to increase.
To get ahead of the curve for your own organization and to find out more about this opportunity, please get in contact with Duncan Emerton, PhD; Director, Custom Intelligence at: [email protected]
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance